Anti-allergic Activity of Stem Bark of Myrica esculenta Buch.-Ham. (Myricaceae)
Abstract
Allergic diseases, such as allergic asthma, are hypersensitivity reactions initiated by immunological mechanisms. Myrica esculenta (M. esculenta) is known traditionally in Ayurveda to possess anti-asthmatic activity. The present investigation was undertaken to evaluate the effect of crude extract of stem bark of M. esculenta (Family Myricaceae, commonly known as Kaiphal) on experimental allergic reactions. Experimental models studied were allergic pleurisy and vascular permeability induced by acetic acid in mice. Pretreatment with M. esculenta (75 mg/kg and 150 mg/kg, p.o.) significantly inhibited the eosinophil accumulation (P < 0.01) respectively in the pleural cavity. M. esculenta (75 and 150 mg/kg, p.o.) significantly inhibited the rise in plasma exudation (57.12% and 59.77%, P < 0.01) induced by acetic acid in mice. These findings demonstrate that the crude extract from the stem bark of M. esculenta possesses antiallergic activity. This activity may be mediated by reducing the release of mediators such as histamine, inhibition of mast cell degranulation, and inhibition of eosinophil accumulation thereby preventing the release of cytokines and chemokines.
INTRODUCTION
Allergic rhinitis and asthma, recognized as immediate-type hypersensitivity reactions, are characterized by increased responsiveness of the tracheobronchial tree to a variety of stimuli, which may be spontaneous, allergen-related, or drug-induced, and the primary pathophysiological abnormality being bronchial wall inflammation leading to airway narrowing.[1–3]
The prevalence and severity of allergic asthma has been steadily increasing over past 20 years together with the number of reported cases of fatal asthma, and it affects up to 10% of the population of most developed countries.[45] The disease statistics clearly necessitates the increasing need for drugs targeting the mechanisms involved in eosinophil and neutrophil activation and accumulation, anti-IgE therapy for the management of asthma. Glucocorticosteroids are the only drugs currently available that effectively reduce airway inflammation in asthma.[6] As a result there is high prevalence of usage of complementary and alternative medicines for treatment of this disease.[7]
Myrica esculenta Buch. Ham. (Syn. Myrica sapida, Family Myricaceae, commonly known as Kaiphal) is known traditionally in Ayurveda for the treatment of asthma and bronchitis.[89] Preliminary studies performed at our laboratory has established the efficacy of M. esculenta in decreasing bronchial hyper-responsiveness and bronchoconstriction through systematic studies on bronchoalveolar lavage, acetyl choline and histamine-induced bronchospasm, and lung cytology in guinea pigs.[1011] The pathophysiology of asthma involves multiple factors leading to hyper-responsiveness and bronchoconstriction, such as mast cell degranulation,[12] neurogenic dysfunction,[13] involvement of T-lymphocytes and eosinophils,[1415] altered immunosuppressive macrophages,[1617] overproduction of proinflammatory cytokines,[1819] immunoglobulins (IgE, IgG, and IgD)[20] and plasma protein exudation.[21–23] Therefore, the present work aims to prove the antiallergic activity based on studies focusing upon inflammation of the airway.
MATERIALS AND METHODS
Plant
Aerial parts of M. esculenta were obtained from commercial supplier of Ahmedabad. The plant was identified and authenticated by Dr. Minoo Parabia, Head and Professor, Department of Bioscience, Veer Narmad South Gujarat University, Surat, Gujarat. A voucher specimen of plant was deposited in the herbarium of the Department of Bioscience, Veer Narmad South Gujarat University, Surat, Gujarat.
Preparation of the plant extract
The aerial parts reduced to coarse powder were macerated with ethanol for 48 h, filtered, and filtrate was evaporated under reduced pressure to obtain a dry extract. The ethanolic extract of M. esculenta (referred to as EtMe) was stored in cool and dry place and used for pharmacological evaluation.
Reagents
Egg albumin and aluminum hydroxide hydrate gel (alum) were purchased from S. D. Fine Chem Limited, India. Freund’s complete adjuvant emulsion, and Evans blue were purchased from HiMedia, India. All other chemicals used were of analytical grade.
Animal protocol
Swiss albino mice of either sex housed in standard conditions of temperature (22 ± 2°C), relative humidity (55 ± 5%), and light (12 hrs light/dark cycles) were used. Animal studies were approved by the Institutional Animal Ethics Committee (protocol no 8004), as per the guidelines of committee for the purpose of control and supervision of experiments on animals (CPCSEA).
Vascular permeability induced by acetic acid[2425]
Swiss albino mice were randomly allocated to four groups each containing six animals. Group I (model control), Group II (standard), Group III (EtMe), and Group IV (EtMe) received saline, indomethacin (20 mg/kg), EtMe (75 mg/kg), and EtMe (150 mg/kg) orally, respectively. Thirty minutes later, mice received an intravenous injection of 0.5% Evans blue saline solution (0.1 ml/10 g body weight) and an intraperitoneal injection of 0.6% acetic acid (10 ml/kg). After 20 min, the dye that leaked into the peritoneal cavity was collected by lavaging with 10 ml distilled water and was transferred to 10 ml volumetric flask through glass wool. To each flask, 0.1 ml of 0.1 N sodium hydroxide solution was added and volume made upto the mark with distilled water followed by measurement of absorbance at 610 nm (Shimadzu Spectrophotometer).
Allergic pleurisy
Swiss albino mice were randomly allocated to five groups each containing six animals: Group I (normal control), Group II (model control), Group III (standard), Group IV (EtMe), and Group V (EtMe). Active sensitization of Swiss albino mice was achieved with a subcutaneous injection of Freund’s complete adjuvant emulsion (100 μL) containing egg albumin (100 μg). Fourteen days later, mice were challenged with an intrathoracic injection of egg albumin (50 μL, 12.5 μg/cavity).[2627] Briefly, an adapted needle was inserted into the right side of the thoracic cavity of egg albumin sensitized animals to permit the intrapleural administration of egg albumin diluted in sterile pyrogen free saline (50 μL). At 24 h after the stimulus, mice were anesthetized and their thoracic cavities were rinsed with 1 mL phosphate buffer saline containing 10 mM EDTA, pH 7.4. Total leukocyte counts were made with an automated cell counter (Cell Dyn 3200SL). Differential cell counts were made by light microscopy stained with Leishman’s stain. Groups IV and V animals fasted overnight and received EtMe (75 mg/kg) and EtMe (150 mg/kg) orally 1 h before stimulation. Group II animals were similarly treated with vehicle alone. In Group III, dexamethasone was given intraperitoneally (2 mg/kg) 24 and 1 h before stimulation.
Statistical analysis
The results of various studies were expressed as mean ± SEM and analyzed statistically using one-way ANOVA with Dunnett post hoc test to find out the level of significance. Data were considered statistically significant at P < 0.05.
RESULTS
Effect of EtMe on vascular permeability induced by acetic acid
Pretreatment with EtMe (75 mg/kg) and EtMe (150 mg/ kg) significantly inhibited the rise in plasma exudation (57.12% and 59.77% inhibition) induced by acetic acid in mice as compared to the control group. Indomethacin (20 mg/kg) also significantly inhibited the exudation (70.69%) [Table 1].
| Group | Evans blue concentration (mg/ml) | % Inhibition |
|---|---|---|
| Control | 1.474 ± 0.121 | - |
| Standard (Indomethacin, 20 mg/kg) | 0.432 ± 0.14* | 70.69 |
| EtMe (75 mg/kg) | 0.632 ± 0.151* | 57.12 |
| EtMe (150 mg/kg) | 0.593 ± 0.222* | 59.77 |
Statistical analysis by one way ANOVA with Dunnett post hoc test; values are mean ± SEM; n = 6 in each group; significantly different from control group
*P < 0.05
Effect of EtMe on allergic pleurisy
Twenty-four hours after the intrathoracic injection of egg albumin, an intense accumulation of total and differential leukocytes was observed in sensitized as compared to the control group. Dexamethasone pre-treatment (2 mg/ kg, i.p.) significantly inhibited the influx of total and differential leukocytes as compared to the sensitized group. The oral pretreatment with EtMe (75 mg/kg and 150 mg/ kg, po) markedly inhibited the eosinophil accumulation as compared to the control group and this inhibition was selective for decrease in the number of eosinophils. Conversely, the number of total leukocytes, lymphocyte, monocytes, and neutrophils was not significantly affected on oral pre-treatment with EtMe (75 mg/kg and 150 mg/kg, po) [Table 2].
| Group | Total leukocyte | Neutrophil | Lymphocyte | Eosinophil | Monocyte |
|---|---|---|---|---|---|
| Control | 3575411 | 1857.75±291.39 | 1567.25±169.71 | 65.5±14.06 | 83.25±17.95 |
| Sensitized | 5225±383.78* | 3072.75±264.34* | 2002±108.44 | 145±27.54* | 111.75±5.63* |
| Dexamethasone (2 mg/kg) | 2550±413.32@ | 1273.5±202.37@ | 1182.25±187.97@ | 32.75±9.3@ | 61.5±20.36 |
| EtMe (75 mg/kg) | 4425±968.14 | 2630.5±761.26 | 1679.5±219.2 | 51.75±8.87 | 63.25±12.92 |
| EtMe (150 mg/kg) | 4423±259.41 | 2319.25±277.2@ | 1938±160.67 | 67±14.29@ | 100.75±15.96 |
Statistical analysis by one-way ANOVA with the Dunnett post hoc test; values are mean ± SEM, n = ± in each group; significantly different from control group;
*P < 0.05 (one-way ANOVA); significantly different from sensitized group;
@P < 0.05 (one-way ANOVA with the Dunnett post hoc test)
DISCUSSION
Allergic processes are complex disorders in which inflammatory and immunological mechanisms are involved. Bronchial asthma is one such allergic process characterized by inflammation of the airways usually accompanied by increased vascular permeability, resulting in plasma exudation. Plasma protein leakage has been implicated to play a role in the induction of a thickened, engorged, and edematous airway wall, resulting in the airway luminal narrowing correlating with bronchial hyper-reactivity and airway inflammation.[2829] It is also possible that the plasma exudates may readily pass the inflamed mucosa and reach the airway lumen through leaky epithelium, thus compromising epithelial integrity and reducing ciliary function and mucus clearance.[3031] It is also reported that increased vascular permeability is associated with bronchial inflammation and airway hyper-responsiveness in a murine model of asthma.[3233] Consistent with these observations, we have found that amounts of plasma extravasation were greatly enhanced in a murine model of allergic airway disease. Interestingly, administration of EtMe inhibited vascular permeability increase thereby inhibiting vascular leakage resulting in decreased airway inflammation and airway hyper-responsiveness.
Additionally, an important causative factor of allergic disease is eosinophilic inflammation.[3435] The triggering and regulation of eosinophil accumulation in allergic inflammation depend on the release of cytokines and chemokines such as interleukin-4 (IL-4), IL-5 and CCL11/eotaxin in response to an antigen challenge.[3637] Among the C-C chemokines, CCL11/eotaxin, an eosinophil-specific chemoattractant, is one of the most important mediators of allergic inflammation, with a potent and selective effect in mobilizing eosinophils from bone marrow to the blood.[37–40] To participate in the allergic inflammatory response, eosinophil must migrate from the circulation to the airway.[4142] Circulating eosinophils migrate to the airways by the phenomenon of cell rolling, through interaction with P-selectin, and eventually adhere to the endothelium through the binding of integrins to adhesion proteins, vascular cell adhesion molecule 1 (VCAM 1) and intercellular adhesion molecule 1 (ICAM 1). As eosinophils enter the matrix of the membrane, their survival is prolonged by IL-5. The cytoplasmic granules of eosinophils have a crystalloid core of major basic protein and a matrix of eosinophil cationic protein, eosinophil-derived neurotoxin, and eosinophil peroxidase that are released on activation. Major basic protein and eosinophil cationic protein have profound cytotoxic effects on the airway epithelium,[43] and for this reason, eosinophils are often regarded as the primary effector cells in asthma. The modulation of eosinophil accumulation is one of the main targets for the discovery of anti-allergic compounds because of its potential tissue damaging effects. Above facts were further substantiated by observing the potential effect of EtMe which produced a pronounced inhibition of eosinophil accumulation in allergic pleurisy, hence decreasing allergic inflammation.
CONCLUSION
Overall data from our experimental studies suggest that ethanolic extract of M. esculenta possesses significant anti-allergic and anti-inflammatory activity and may be useful in the treatment of allergic disorders such as allergic asthma and allergic rhinitis by decreasing bronchial hyper-responsiveness.
Footnotes
Source of Support: Nil
Conflict of Interest: None declared.
References
- 1. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, Nov 1986Am Rev Respir Dis198713622544[PubMed][Google Scholar]
- 2. Asthma. Definition and clinical spectrumBr Med Bull19924819[PubMed][Google Scholar]
- 3. Pathology of asthmaBr Med Bull1992482339[PubMed][Google Scholar]
- 4. The many faces of airway inflammation-Asthma and Chronic obstructive pulmonary diseaseAm J Respir Crit Care Med1999159S4166[PubMed][Google Scholar]
- 5. Phosphodiesterase 4 inhibitors and the treatment of asthma-where are we now and where do we go from hereDrugs200059193212[PubMed][Google Scholar]
- 6. Efficacy and safety of inhaled corticosteroids in asthma. Report of a workshop held in Eze, France, October 1992Am Rev Respir Dis1993148S126[PubMed][Google Scholar]
- 7. Allergic rhinitis: Past, present and the futureClin Otolaryngol Allied Sci200328291303[PubMed][Google Scholar]
- 8. Indian Medicinal Plants1999Vol. III2nd editionInternational book distributors1699
- 9. Indian Materia Medica2002Vol. I3rd revised edition871Nadkarni’s KM Indian Materia Medica, 3 rd revised edition, Vol I, Popular Prakashan Pvt Ltd; 2002 p 871
- 10. Evaluation of the effect of Myrica sapida on bronchoconstriction and bronchial hyperreactivityPharmazie2008633126[PubMed][Google Scholar]
- 11. Evaluation of bronchodilator and antianphylactic activity of Myrica sapidaIran Biomed J2008121916[PubMed][Google Scholar]
- 12. Essentials of Clinical Immunology19994th ednOxfordBlackwell Science104
- 13. Mechanism of airway inflammation in asthmaAm Rev Respir Dis19931475204[Google Scholar]
- 14. T-cell and eosinophils in the pathogenesis of asthmaImmunol Today1992135017[PubMed][Google Scholar]
- 15. T-lymphocyte dysregulation in asthmaProc Soc Exp Biol Med199420724353[PubMed][Google Scholar]
- 16. Immunological/Physiological relationships in asthma: Potential regulation by lung macrophagesImmunol Today199415258261[PubMed][Google Scholar]
- 17. Characterization of immune inducer and suppressor macrophage from normal human lungClin Exp Immunol19918315762[PubMed][Google Scholar]
- 18. Nitric oxide and asthmatic inflammationImmunol Today19911612830[PubMed][Google Scholar]
- 19. Tumour necrosis factors in childhood AsthmaIndian J Pediatr20016821722[PubMed][Google Scholar]
- 20. Immunoglobulin isotypes in childhood asthmaIndian J Pediatr19996633744[PubMed][Google Scholar]
- 21. Cysteinyl leukotriene receptor antagonist regulates vascular permeability by reducing vascular endothelial growth factor expressionJ Allergy Clin Immunol200411410939[PubMed][Google Scholar]
- 22. Contribution of vascular endothelial growth factor to airway hyperresponsiveness and inflammation in a murine model of toluene diisocyanate induced asthmaJ Immunol20021683595600[PubMed][Google Scholar]
- 23. Angiopoietin-1 protects the adult vasculature against plasma leakageNat Med200064603[PubMed][Google Scholar]
- 24. The use of changes in capillary permeability in mice to distinguish between narcotic and nonnarcotic analgesicsBr J Pharmacol Chemother19642224653[PubMed][Google Scholar]
- 25. Berberis crataegina DC. root exhibits potent anti-inflammatory, analgesic and febrifuge effects in mice and ratsJ Ethnopharmacol20027923748[PubMed][Google Scholar]
- 26. Role of endothelins on lymphocyte accumulation in allergic pleurisyJ Leukoc Biol20006718995[PubMed][Google Scholar]
- 27. Differential inhibition by two hetrazepine PAF antagonists of acute inflammation in the mouseBr J Pharmacol1990991648[PubMed][Google Scholar]
- 28. Angiopoietin-1 protects the adult vasculature against plasma leakageNat Med200064603[PubMed][Google Scholar]
- 29. Respiratory membrane permeability and bronchial hyperreactivity in patients with stable asthma. Effects of therapy with inhaled steroidsAm Rev Respir Dis19911433628[PubMed][Google Scholar]
- 30. Epithelial cells: Barrier functions and sheddingrestitution mechanismsAm J Respir Crit Care Med1996153S910[PubMed][Google Scholar]
- 31. Lung mucociliary function in man: Interdependence of bronchial and tracheal mucus transport velocities with lung clearance in bronchial asthma and healthy subjectsAnn Occup Hyg19822622744[PubMed][Google Scholar]
- 32. Cysteinyl leukotriene receptor antagonist regulates vascular permeability by reducing vascular endothelial growth factor expressionJ Allergy Clin Immunol200411410939[PubMed][Google Scholar]
- 33. Contribution of vascular endothelial growth factor to airway hyperresponsiveness and inflammation in a murine model of toluene diisocyanate induced asthmaJ Immunol20021683595600[PubMed][Google Scholar]
- 34. Clinical usefulness of inflammatory markers in asthmaAm J Respir Med20032119[PubMed][Google Scholar]
- 35. Advances in mechanisms of allergyJ Allergy Clin Immunol200411386875[PubMed][Google Scholar]
- 36. Activation of CD4+T cells, increased TH2-type cytokine mRNA expression, and eosinophil recruitment in bronchoalveolar lavage after allergen inhalation challenge in patients with atopic asthmaJ Allergy Clin Immunol19939231324[PubMed][Google Scholar]
- 37. Eotaxin induces a rapid release of eosinophils and their progenitors from the bone marrowBlood19989122408[PubMed][Google Scholar]
- 38. Eotaxin: A potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammationJ Exp Med19941798817[Google Scholar]
- 39. Murine eotaxin: An eosinophil chemoattractant inducible in endothelial cells and in interleukin 4-induced tumor suppressionProc Natl Acad Sci U S A19959289604[PubMed][Google Scholar]
- 40. Human chemokines: An updateAnnu Rev Immunol199715675705[PubMed][Google Scholar]
- 41. Cellular adhesion and its antagonismJ Allergy Clin Immunol19971005815[PubMed][Google Scholar]
- 42. Molecular basis for selective eosinophil trafficking in asthma: A multistep paradigmJ Allergy Clin Immunol199910491726[PubMed][Google Scholar]
- 43. Immunological aspects of asthma: Implications for future treatmentClin Immunol Ther199413142[Google Scholar]